Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

2
ARQL / ArQule, Inc. FINAL PROSPECTUS SUPPLEMENT (Prospectus)

2018-07-12 sec.gov
tv498327-424b5 - none - 3.4245855s TABLE OF CONTENTS
ARQL

10
ARQL / ArQule, Inc. PRELIMINARY PROSPECTUS SUPPLEMENT (Prospectus)

2018-07-10 sec.gov
tv498226-424b5 - none - 3.032343s TABLE OF CONTENTS
ARQL

5
ArQule: Continued Upside As Additional Catalysts Loom

2018-07-08 seekingalpha
AKT inhibitor miransertib in certain oncology and rare disease indications will increasingly garner attention in the second half of the year.
SAGE SNSS BPMUF ARQL ARIA

56
Biotech: Take It On The Run

2018-07-05 seekingalpha
Jonathan Faison, author of ROTY on Marketplace, says his approach to biotech investing offers a framework for disciplined decision-making.
BLCM SLDB GLMD LOXO INCY ARQL NTEC KDMN SRPT MGTX AQXP 4508 IFRX MTZXF ARGX GWPH MTZPY NVS CTMX GWP

2
ARQL / ArQule, Inc. null

2018-07-05 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C<@,"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S$Y M.3$O3R [email protected],C
ARQL

2
ARQL / ArQule, Inc. null

2018-07-05 sec.gov
May 29, 2018 VIA EDGAR U.S. Securities and Exchange Commission
ARQL

49
Sunesis Pharmaceuticals: A Run-Up Interrupted Set To Resume?

2018-06-27 seekingalpha
The growing gap in valuation is intriguing, and an update on the clinical progress of SNS-062 in fall represents a near-term catalyst.
SNSS ARQL APTO APS

9
ArQule: Elucidating The Prospects Of An Interesting Grower

2018-06-21 seekingalpha
As a small market cap, ArQule is brewing a highly enriched and extensive pipeline promising kinase inhibitors to service the oncology market.
BPMUF ARQL

9
ARQL / ArQule, Inc. / INTEGRATED CORE STRATEGIES (US) LLC - null (Passive Investment)

2018-06-18 sec.gov
SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ARQULE, INC.
ARQL

9
ARQL / ArQule, Inc. / INTEGRATED CORE STRATEGIES (US) LLC - null (Passive Investment)

2018-06-18 sec.gov
SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ARQULE, INC.
ARQL

37
Three Biotechs With Upcoming Data At Conferences

2018-06-11 seekingalpha
Biotech stocks tend to have strong movement when their respective companies have binary events upcoming in short order.
MYOK CYTK ARQL APR APRLY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

12h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

13h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ARQL / ArQule, Inc. on message board site Silicon Investor.

ArQule, Inc. (ARQL) ArQule (ARQL)
ArQule
CUSIP: 04269E107